

**Section I (Amendments to the Claims)**

Please amend claim 20 as set out in the following listing of the claims of the application.

Please cancel claims 1-3, 5, 6, 8-19 and 28 without prejudice.

Upon entry of the present amendment, the claims will stand as follows. The following listing of the claims will replace all prior versions and listings of the claims in the present application:

Claims 1-19 (Canceled).

20. **(Currently Amended)** A conjugate suited for treating prokaryotic infections, comprising the following components:
- (a) a phage-holin protein ~~protein or a defensin~~ as transport peptide or protein adapted to penetrate the prokaryotic cell membrane; and linked by a covalent bond thereto; and
  - (b) a peptide nucleic acid (PNA) to be introduced into the prokaryote and directed against a DNA of a gene giving antibiotic resistance, wherein the peptide nucleic acid inhibits the transcription of the gene.
21. **(Previously Presented)** The conjugate according to claim 20, wherein the bacterium is a bacterium pathogenic for humans.
22. **(Previously Presented)** The conjugate according to claim 20, wherein the transport peptide or protein is a phage-holin protein comprising one of the amino acid sequences of SEQ ID NOs: 4 to 31.
23. **(Previously Presented)** The conjugate according to claim 20, wherein the antibiotic resistance is a resistance to penicillin, ampicillin, kanamycin or tetracycline.
24. **(Previously Presented)** The conjugate according to claim 20, which has the following structure: transport peptide or protein-spacer-peptide nucleic acid (PNA).
25. **(Previously Presented)** The conjugate or conjugate mixture according to claim 24, wherein the spacer is polylysine, polyglycine or poly(glycine/lysine).

4121-170

26. **(Previously Presented)** The conjugate according to claim 24, wherein the spacer is linked to the transport peptide or protein via a cleavable disulfide bridge.
27. **(Previously Presented)** The conjugate according to claim 20, wherein the peptide nucleic acid comprises the sequence H<sub>2</sub>N-ATTGTTAGATTTCAT-COOH (SEQ ID NO:1).
28. **(Canceled).**
29. **(Previously Presented)** A medicament comprising the conjugate according to claim 20.
30. **(Previously Presented)** The medicament according to claim 29, further comprising at least one antibiotic for which the prokaryote was re-sensitized by administering the conjugate.